Chun-Su Lee
Comptroller/Controller/Auditor chez NOVMETAPHARMA CO., LTD.
Fortune : 222 677 $ au 31/05/2024
Profil
Chun-Su Lee is currently working as an Auditor at NovMetaPharma Co., Ltd.
and NovMetaHealth Co. Ltd.
He completed his undergraduate and graduate degrees from Korea University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NOVMETAPHARMA CO., LTD.
0,44% | 30/06/2023 | 48 860 ( 0,44% ) | 222 677 $ | 31/05/2024 |
Postes actifs de Chun-Su Lee
| Sociétés | Poste | Début |
|---|---|---|
| NOVMETAPHARMA CO., LTD. | Comptroller/Controller/Auditor | 31/03/2015 |
NovMetaHealth Co. Ltd.
 NovMetaHealth Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of NovMetaPharma Co., Ltd., NovMetaHealth Co. Ltd. develops and manufactures products related to metabolic diseases. The company is based in Seoul, South Korea. The South Korean company was founded in 2016. Seon-Wook Hwang has been the CEO of the company since 2016. NovMetaHealth Co. was acquired by NovMetaPharma Co., Ltd. on March 10, 2022 for $12.61 million. | Comptroller/Controller/Auditor | 01/12/2018 |
Formation de Chun-Su Lee
| Korea University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVMETAPHARMA CO., LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
NovMetaHealth Co. Ltd.
NovMetaHealth Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of NovMetaPharma Co., Ltd., NovMetaHealth Co. Ltd. develops and manufactures products related to metabolic diseases. The company is based in Seoul, South Korea. The South Korean company was founded in 2016. Seon-Wook Hwang has been the CEO of the company since 2016. NovMetaHealth Co. was acquired by NovMetaPharma Co., Ltd. on March 10, 2022 for $12.61 million. | Health Technology |
